PT - JOURNAL ARTICLE AU - Morera Maiquez, Barbara AU - Smith, Caitlin AU - Dyke, Katherine AU - Chou, Chia-Ping AU - Kasbia, Belinda AU - McCready, Ciara AU - Wright, Hannah AU - Jackson, Jessica K. AU - Farr, Isabel AU - Badinger, Erika AU - Jackson, Georgina M. AU - Jackson, Stephen R. TI - A double-blind, sham-controlled, trial of home-administered rhythmic 10Hz median nerve stimulation for the reduction of tics, and suppression of the urge-to-tic, in individuals with Tourette syndrome and chronic tic disorder AID - 10.1101/2023.03.06.23286799 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.06.23286799 4099 - http://medrxiv.org/content/early/2023/03/07/2023.03.06.23286799.short 4100 - http://medrxiv.org/content/early/2023/03/07/2023.03.06.23286799.full AB - Tourette syndrome (TS) and chronic tic disorder (CTD) are neurological disorders of childhood onset characterised by the occurrence of tics; repetitive, purposeless, movements or vocalisations of short duration which can occur many times throughout a day. Currently, effective treatment for tic disorders is an area of considerable unmet clinical need. We aimed to evaluate the efficacy of a home-administered neuromodulation treatment for tics involving the delivery of rhythmic pulse trains of median nerve stimulation (MNS) delivered via a wearable ‘watch-like’ device worn at the wrist. We conducted a UK-wide parallel double-blind sham-controlled trial for the reduction of tics in individuals with tic disorder. The device was programmed to deliver rhythmic (10Hz) trains of low-intensity (1-19 mA) electrical stimulation to the median nerve for a pre-determined duration each day, and was intended to be used by each participant in their home once each day, 5 days each week, for a period of 4 weeks. Between 18th March 2022 and 26th September 2022 135 participants (45 per group) were initially allocated, using stratified randomisation, to one of the following groups; active stimulation; sham stimulation; or a to waitlist (i.e., treatment as usual) control group. Recruited participants were individuals with confirmed or suspected TS/CTD aged 12 years of age or upward with moderate to severe tics. Researchers involved in the collection or processing of measurement outcomes and assessing the outcomes, as well as participants in the active and sham groups and their legal guardians were all blind to the group allocation. The primary outcome measure used to assess the ‘offline’ or treatment effect of stimulation was the Yale Global Tic Severity Scale - Total Tic Severity Score (YGTSS-TTSS) assessed at the conclusion of 4-weeks of stimulation. The primary outcome measure used to assess the ‘online’ effects of stimulation was tic frequency, measured as the number of tics per minute (TPM) observed, based upon blind analysis of daily video recordings obtained while stimulation was delivered. The results demonstrated that after 4-weeks stimulation, tic severity (YGTSS-TTSS) had reduced by 7.1 points (35% reduction) for the active stimulation group compared to 2.13/2.11points for the sham stimulation and waitlist control groups. The reduction in YGTSS-TTSS for the active stimulation group was substantially larger, clinically meaningful (effect size = 0.5), and statistically significant (p = 0.02) compared to both the sham stimulation and waitlist control groups, which did not differ from one another (effect-size = -0.03). Furthermore, blind analyses of video recordings demonstrated that tic frequency (tics per minute) reduced substantially (−15.6 TPM) during active stimulation compared to sham stimulation (−7.7 TPM). This difference represents a statistically significant (p < 0.03) and clinically meaningful reduction in tic frequency (> 25% reduction: effect-size = 0.3). These findings indicate that home-administered rhythmic MNS delivered through a wearable wrist-worn device has potential as an effective community-based treatment for tic disorders.Competing Interest StatementThis study reports a clinical trial that was conducted by the University of Nottingham in partnership with the Nottingham University Hospitals NHS Trust and Neurotherapeutics Ltd, a University of Nottingham spin-out company. Neurotherapeutics supplied the Neupulse devices used in the clinical trial and several of the study authors were employees of Neurotherapeutics Ltd during the completion of the trial and participated in double-blind data collection. These were: Barbara Morera Marquez; Chia-Ping Chou; Belinda Kasbiac; Ciara McCready; Hannah Wright; and Jessica K. Jackson. Analyses of the data were conducted independently by University of Nottingham scientists.Clinical TrialNCT05269953Funding StatementThis work was supported by grants awarded by: Tourettes Action (UK); The Tourettes Association of America; The Medical Research Council; and the NIHR Nottingham Biomedical Research Centre. Neurotherapeutics Ltd provided the Neupulse devices used in this trial and funded the employment of several members of the research team responsible for data collection, i.e., Chia-Ping Chou, Belinda Kasbia, Ciara McCready, Hannah Wright, and Jessica K. Jackson.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:East Midlands - Leicester South Research Ethics Committee gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study will be available on request from the corresponding author [SRJ]. The data are not publicly available due to ethical restrictions as they contain information that could compromise the privacy of research participants.